Hester Biosciences schedules board meeting on 15 May 2026 to approve audited standalone and consolidated financial results for Q4 and FY ending 31 March 2026.
The board will consider declaration of dividend for financial year 2025-26, subject to their decision.
Disclosure made under SEBI Listing Regulations Regulation 29 for mandatory intimation of board meetings.